Engineering rna for targeted sirna delivery and medical application

Advanced Drug Delivery Reviews

Volumn 62, Issue 6, 2010, Pages 650-666

  Guo, Peixuan ^a   Coban, Oana ^a   Snead, Nicholas M ^b   Trebley, Joe ^c   Hoeprich, Steve ^b   Guo, Songchuan ^c   Shu, Yi ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Kylin Therapeutics Inc   (United States)

Author keywords

Bacteriophage phi29; DNA translocation; Gene therapy; Hexameric ring; Nanobiotechnology; Nanomedicine; PRNA; Procapsid; RNA dimer; RNA nanotechnology; SiRNA; Targeted delivery; Trimer; Viral assembly; Viral DNA packaging motor

Indexed keywords

BACTERIOPHAGE PHI29; DNA TRANSLOCATION; HEXAMERIC RING; HEXAMERIC RINGS; NANOMEDICINE; NANOMEDICINES; SIRNA; TARGETED DELIVERY; VIRAL DNA;

BACTERIOPHAGES; DIAGNOSIS; DNA; DRUG THERAPY; GENE EXPRESSION; GENETIC ENGINEERING; LIGANDS; MEDICAL NANOTECHNOLOGY; NUCLEIC ACIDS; RNA;

GENE THERAPY;

ANTINEOPLASTIC AGENT; APTAMER; CARBOHYDRATE; CHITOSAN; COMPLEMENTARY RNA; CYCLODEXTRIN; DENDRIMER; DOXORUBICIN; DRUG CARRIER; DRUG VEHICLE; FOMIVIRSEN; LIGAND; LIPOSOME; MACROGOL; MICRORNA; MONOCLONAL ANTIBODY; NANOCARRIER; NANOPARTICLE; NUCLEIC ACID; OLIGONUCLEOTIDE; PACLITAXEL; PEPTIDE DERIVATIVE; POLYETHYLENEIMINE; POLYMER; PROTEIN DERIVATIVE; RIBOZYME; SMALL INTERFERING RNA; TRANSFERRIN; UNINDEXED DRUG; VINCRISTINE;

APOPTOSIS; CANCER GENE THERAPY; CANCER RESISTANCE; CELL CYCLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS RETINITIS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; RNA STABILITY; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TUMOR VASCULARIZATION; VIRUS INFECTION;

ANIMALS; APTAMERS, NUCLEOTIDE; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GENE TARGETING; GENE THERAPY; HUMANS; LIPOSOMES; MICE; MOLECULAR CONFORMATION; RNA; RNA, SMALL INTERFERING; SELEX APTAMER TECHNIQUE;

EID: 77953609202     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.03.008     Document Type: Review

References (199)

1. Niemeyer C.M. The developments of semisynthetic DNA-protein conjugates. Trends Biotechnol. 2002, 20:395-401.
2. Schmidt O.G., Eberl K. Nanotechnology. Thin solid films roll up into nanotubes. Nature 2001, 410:168.
3. Baneyx G., Baugh L., Vogel V. Fibronectin extension and unfolding within cell matrix fibrils controlled by cytoskeletal tension. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:5139-5143.
4. Hyman P., Valluzzi R., Goldberg E. Design of protein struts for self-assembling nanoconstructs. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8488-8493.
5. Goldberger J., He R., Zhang Y., Lee S., Yan H., Choi H.J., Yang P. Single-crystal gallium nitride nanotubes. Nature 2003, 422:599-602.
6. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 1989, 244:48-52.
7. Jaeger J.A., SantaLucia J.J., Tinoco I.J. Determination of RNA structure and thermodynamics. Annu. Rev. Biochem. 1993, 62:255-285.
8. Pleij C.W., Bosch L. RNA pseudoknots: Structure, Detection, and Prediction. Methods Enzymol. 1989, 180:289-303.
9. Correll C.C., Freeborn B., Moore P.B., Steitz T.A. Metals, motifs, and recognition in the crystal structure of a 5S rRNA domain. Cell 1997, 91:705-712.
10. Guo P., Nanotechnology R.N.A. Engineering: Assembly and Applications in Detection, Gene Delivery and Therapy. J. Nanosci. Nanotechnol. 2005, 5(12):1964-1982.
11. Shu D., Moll W.D., Deng Z., Mao C., Guo P. Bottom-up assembly of RNA arrays and superstructures as potential parts in nanotechnology. Nano Lett. 2004, 4:1717-1723.
12. Jaeger L., Leontis N.B. Tecto-RNA: One dimensional self-assembly through tertiary interactions. Angew. Chem. Int. Ed. Engl. 2000, 39:2521-2524.
13. Hansma H.G., Oroudjev E., Baudrey S., Jaeger L. TectoRNA and 'kissing-loop' RNA: atomic force microscopy of self-assembling RNA structures. J. Microsc. 2003, 212:273-279.
14. Forster A.C., Symons R.H. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 1987, 49:211-220.
15. Sarver N.A., Cantin E.M., Chang P.S., Zaia J.A., Ladne P.A., Stephens D.A., Rossi J.J. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990, 247:1222-1225.
16. Chowrira B.M., Berzal-Herranz A., Burke J.M. Novel guanosine requirement for catalysis by the hairpin ribozyme. Nature 1991, 354:320-322.
17. Kruger K., Grabowski P.J., Zaug A.J., Sands J., Gottschling D.E., Cech T.R. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982, 31:147-157.
18. Zaug A.J., Grabowski P.J., Cech T.R. Autocatalytic cyclization of an excised intervening sequence RNA is a cleavage-ligation reaction. Nature 1983, 301:578-583.
19. Guerrier-Takada C., Gardiner K., Marsh T., Pace N., Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983, 35:849-857.
20. Kashani-Sabet M. Ribozyme therapeutics. J. Investig. Dermatol. Symp. Proc. 2002, 7:76-78.
21. Li M.J., Kim J., Li S., Zaia J., Yee J.K., Anderson J., Akkina R., Rossi J.J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12:900-909.
22. Bratty J., Chartrand P., Ferbeyre G., Cedergren R. The hammerhead RNA domain, a model ribozyme. Biochim. Biophys. Acta 1993, 1216:345-359.
23. Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Prog. Nucleic Acid Res. Mol. Biol. 1998, 58:1-39.
24. Guo P., Erickson S., Anderson D. A small viral RNA is required for in vitro packaging of bacteriophage phi29 DNA. Science 1987, 236:690-694.
25. Chen C., Zhang C., Guo P. Sequence requirement for hand-in-hand interaction in formation of pRNA dimers and hexamers to gear phi29 DNA translocation motor. RNA 1999, 5:805-818.
26. Cech T.R. Self-splicing of group I introns. Annu. Rev. Biochem. 1990, 59:543-568.
27. Pace N.R., Brown J.W. Evolutionary perspective on the structure and function of ribonuclease P, a ribozyme. J. Bacteriol. 1995, 177:1919-1928.
28. Hoeprich S., ZHou Q., Guo S., Qi G., Wang Y., Guo P. Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene Ther. 2003, 10:1258-1267.
29. Liu H., Guo S., Roll R., Li J., Diao Z., Shao N., Riley M.R., Cole A.M., Robinson J.P., Snead N.M., Shen G., Guo P. Phi29 pRNA Vector for Efficient Escort of Hammerhead Ribozyme Targeting Survivin in Multiple Cancer Cells. Cancer Biol. Ther. 2007, 6:697-704.
30. Coleman J., Hirashima A., Inocuchi Y., Green P.J., Inouye M. A novel immune system against bacteriophage infection using complementary RNA (micRNA). Nature 1985, 315:601-603.
31. Knecht D.A., Loomis W.F. Antisense RNA inactivation of myosin heavy chain gene expression in Dictyostelium discoideum. Science 1987, 236:1081-1086.
32. Melnikova I. RNA-based therapies. Nat. Rev. Drug Discov. 2007, 6:863-864. (Ref Type: Generic).
33. Perry C.M., Balfour J.A. Fomivirsen. Drugs 1999, 57:375-380.
34. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
35. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
36. Hamilton A.J., Baulcombe D.C. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999, 286:950-952.
37. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
38. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15:188-200.
39. Couzin J. Nobel Prize in Physiology or Medicine: Method to Silence Genes Earns Loud Praise. Science 2006, 314:34.
40. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
41. Hough S.R., Wiederholt K.A., Burrier A.C., Woolf T.M., Taylor M.F. Why RNAi makes sense. Nat. Biotechnol. 2003, 21:731-732.
42. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
43. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA ploymerase. Science 1990, 249:505-510.
44. Klug S.J., Famulok M. All you wanted to know about SELEX. Mol. Biol. Rep. 1994, 20:97-107.
45. Marshall K.A., Ellington A.D. In vitro selection of RNA aptamers. Methods Enzymol. 2000, 318:193-214.
46. Ellington A.D., Szostak J.W. Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature 1992, 355:850-852.
47. Conrad R.C., Baskerville S., Ellington A.D. In vitro selection methodologies to probe RNA function and structure. Mol. Divers. 1995, 1:69-78.
48. Shu D., Guo P. A Viral RNA that binds ATP and contains an motif similar to an ATP-binding aptamer from SELEX. J. Biol. Chem. 2003, 278(9):7119-7125.
49. Gold L. The SELEX process: a surprising source of therapeutic and diagnostic compounds. Harvey Lect. 1995, 91:47-57.
50. Clark S., Remcho V. Aptamers as analytical reagents. Electrophoresis 2002, 23:1335-1340.
51. Bouvet P. Determination of nucleic acid recognition sequences by SELEX. Methods Mol. Biol. 2001, 148:603-610.
52. Wang C., Jin Y.X., Wang D.B. Selection with SELEX Method of Small RNA Molecules Specifically Binding to Starch. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao. (Shanghai) 1998, 30:402-404.
53. Kraus E., James W., Barclay A.N. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J. Immunol. 1998, 160:5209-5212.
54. Khaled A., Guo S., Li F., Guo P. Controllable Self-Assembly of Nanoparticles for Specific Delivery of Multiple Therapeutic Molecules to Cancer Cells Using RNA Nanotechnology. Nano Lett. 2005, 5:1797-1808.
55. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
56. Zhou J., Li H., Zaia J., Rossi J.J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 2008, 16:1481-1489.
57. Zhou J., Swiderski P., Li H., Zhang J., Neff C.P., Akkina R., Rossi J.J. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009, 37:3094-3109.
58. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
59. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
60. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., Carter B.J., Davidson B.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5868-5873.
61. Soifer H.S., Rossi J.J., Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol. Ther. 2007, 15:2070-2079.
62. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA 2004, 10:766-771.
63. Lewis D.L., Wolff J.A. Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol. 2005, 392:336-350.
64. Shen J., Samul R., Silva R.L., Akiyama H., Liu H., Saishin Y., Hackett S.F., Zinnen S., Kossen K., Fosnaugh K., Vargeese C., Gomez A., Bouhana K., Aitchison R., Pavco P., Campochiaro P.A. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2005, 13:225-234.
65. Ye J.D., Tereshko V., Frederiksen J.K., Koide A., Fellouse F.A., Sidhu S.S., Koide S., Kossiakoff A.A., Piccirilli J.A. Synthetic antibodies for specific recognition and crystallization of structured RNA. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:82-87.
66. Corey D.R. Chemical modification: the key to clinical application of RNA interference?. J. Clin. Investig. 2007, 117:3615-3622.
67. Ravikumar V.T., Andrade M., Carty R.L., Dan A., Barone S. Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS). Bioorg. Med. Chem. Lett. 2006, 16:2513-2517.
68. Choung S., Kim Y.J., Kim S., Park H.O., Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 2006, 342:919-927.
69. S.G., Overhoff M. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep. 2005, 6:1176-1181.
70. M. Stessl, M. Marchetti-Deschmann, J. Winkler, B. Lachmann, G. Allmaier, and C.R. Noe, A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells., J Proteomics., In print (2009).
71. Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 2004, 8:570-579.
72. Hall A.H., Wan J., Shaughnessy E.E., Ramsay Shaw B., Alexander K.A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004, 32:5991-6000.
73. Kawasaki A.M., Casper M.D., Freier S.M., Lesnik E.A., Zounes M.C., Cummins L.L., Gonzalez C., Cook P.D. Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 1993, 36:831-841.
74. Rusckowski M., Qu T., Roskey A., Agrawal S. Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice. Antisense Nucleic Acid Drug Dev. 2000, 10:333-345.
75. Pieken W.A., Olsen D.B., Benseler F., Aurup H., Eckstein F. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 1991, 253:314-317.
76. Parrish S., Fleenor J., Xu S., Mello C., Fire A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell 2000, 6:1077-1087.
77. Elmen J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y., Wahren B., Liang Z., Orum H., Koch T., Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005, 33:439-447.
78. Luo G., Sharmeen L., Taylor J. Specificities Involved in the Initiation of Retroviral Plus-Strand DNA. J. Virol. 1990, 64:592-597.
79. Chen P.Y., Weinmann L., Gaidatzis D., Pei Y., Zavolan M., Tuschl T., Meister G. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008, 14:263-274.
80. Mook O.R., Baas F., de Wissel M.B., Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther. 2007, 6:833-843.
81. Chiu Y.L., Rana T.M. siRNA function in RNAi: a chemical modification analysis. RNA 2003, 9:1034-1048.
82. Song E., Lee S.K., Dykxhoorn D.M., Novina C., Zhang D., Crawford K., Cerny J., Sharp P.A., Lieberman J., Manjunath N., Shankar P. Sustained Small Interfering RNA-Mediated Human Immunodeficiency Virus Type 1 Inhibition in Primary Macrophages. J. Virol. 2003, 77:7174-7181.
83. Parrish J.Z., Xue D. Functional genomic analysis of apoptotic DNA degradation in C. elegans. Mol. Cell 2003, 11:987-996.
84. Ui-Tei K., Naito Y., Zenno S., Nishi K., Yamato K., Takahashi F., Juni A., Saigo K. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008, 36:2136-2151.
85. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2:711-719.
86. Lorenz C., Hadwiger P., John M., Vornlocher H.P., Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004, 14:4975-4977.
87. Guo S., Huang F., Guo P. Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther. 2006, 13:814-820.
88. Zhang K., Wang Q., Xie Y., Mor G., Sega E., Low P.S., Huang Y. Receptor-mediated delivery of siRNAs by tethered nucleic acid base-paired interactions. RNA 2008, 14:577-583.
89. Kim D.H., Behlke M.A., Rose S.D., Chang M.S., Choi S., Rossi J.J. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 2005, 23:222-226.
90. Kim D.H., Longo M., Han Y., Lundberg P., Cantin E., Rossi J.J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 2004, 22:321-325.
91. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6:443-453.
92. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8:173-184.
93. De Paula D., Bentley M.V., Mahato R.I. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007, 13:431-450.
94. Xu S., Dong M., Liu X., Howard K.A., Kjems J., Besenbacher F. Direct Force Measurements between siRNA and Chitosan Molecules Using Single-Molecule Force Spectroscopy. Biophys. J. 2007, 93:952-959.
95. Jain K.K. The role of nanobiotechnology in drug discovery. Drug Discov. Today 2005, 10:1435-1442.
96. Li W., Szoka F. Lipid-based Nanoparticles for Nucleic Acid Delivery. Pharm. Res. 2007, 24:438-449.
97. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9469-9474.
98. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 2006, 116:123-129.
99. Guo S., Tschammer N., Mohammed S., Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum. Gene Ther. 2005, 16:1097-1109.
100. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 1994, 271:58-65.
101. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990, 9:253-266.
102. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 1989, 81:570-576.
103. Tanaka T., Shivamoto S., Miyashita M., Fujishima Y., Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 2004, 277:39-61.
104. Iyer A.K., Greish K., Seki T., Okazaki S., Fang J., Takeshita K., Maeda H. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug Target. 2007, 15:496-506.
105. Wong H.L., Bendayan R., Rauth A.M., Xue H.Y., Babakhanian K., Wu X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 2006, 317:1372-1381.
106. H.M. Zhang, Y. Su, S. Guo, J. Yuan, T. Lim, J. Liu, P. Guo, D. Yang, Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs. Antiviral Res., 83 (2009) 307-316.
107. Pichler A., Zelcer N., Prior J.L., Kuil A.J., Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin. Cancer Res. 2005, 11:4487-4494.
108. Yokota T., Miyagishi M., Hino T., Matsumura R., Tasinato A., Urushitani M., Rao R.V., Takahashi R., Bredesen D.E., Taira K., Mizusawa H. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. Biochem. Biophys. Res. Commun. 2004, 314:283-291.
109. Okamoto K., Ocker M., Neureiter D., Dietze O., Zopf S., Hahn E.G., Herold C. bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J. Cell. Mol. Med. 2007, 11:349-361.
110. Kanda T., Yokosuka O., Imazeki F., Arai M., Saisho H. Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. DNA Cell Biol. 2005, 24:805-809.
111. Han Z., Hong L., Wu K., Han S., Shen H., Liu C., Han Y., Liu Z., Han Y., Fan D. Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA. J. Exp. Clin. Cancer Res. 2006, 25:601-606.
112. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2004, 11:915-923.
113. Ning S., Fuessel S., Kotzsch M., Kraemer K., Kappler M., Schmidt U., Taubert H., Wirth M.P., Meye A. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int. J. Oncol. 2004, 25:1065-1071.
114. Yonesaka K., Tamura K., Kurata T., Satoh T., Ikeda M., Fukuoka M., Nakagawa K. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int. J. Cancer 2006, 118:812-820.
115. Ai Z., Yin L., Zhou X., Zhu Y., Zhu D., Yu Y., Feng Y. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 2006, 107:746-756.
116. S. Weikert, M. Schrader, M. Muller, W. Schulze, H. Krause, and K. Miller, Expression levels of the inhibitor of apoptosis survivin in testes of patients with normal spermatogenesis and spermatogenic failure, Fertil. Steril. 2005 Apr, (1983) 1100-1105.
117. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3:46-54.
118. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
119. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007, 28:1133-1139.
120. Wohlbold L., Kuip H.V.D., Miething C., Vornlocher H.P., Knabbe C., Duyster J., Aulitzky W.E. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003, 102:2236-2239.
121. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005, 12:461-466.
122. Pirollo K.F., Rait A., ZHou Q., Hwang S.H., Dagata J.A., Zon G., Hogrefe R.I., Palchik G., Chang E.H. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 2007, 67:2938-2943.
123. Kim W.J., Chang C.W., Lee M., Kim S.W. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J. Control. Release 2007, 118:357-363.
124. Pichler A., Zelcer N., Prior J.L., Kuil A.J., Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin. Cancer Res. 2005, 11:4487-4494.
125. Van Rij R.P., Andino R. The silent treatment: RNAi as a defense against virus infection in mammals. Trends Biotechnol. 2006, 24:186-193.
126. Novina C.D., Murray M.F., Dykxhoorn D.M., Beresford P.J., Riess J., Lee S.K., Collman R.G., Lieberman J., Shankar P., Sharp P.A. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 2002, 8:681-686.
127. Chang L.J., Liu X., He J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther. 2005, 12:1133-1144.
128. Ge Q., Filip L., Bai A., Nguyen T., Eisen H.N., Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8676-8681.
129. Mallanna S.K., Rasool T.J., Sahay B., Aleyas A.G., Ram H., Mondal B., Nautiyal B., Premraj A., Sreekumar E., Yadav M.P. Inhibition of Anatid Herpes Virus-1 replication by small interfering RNAs in cell culture system. Virus Res. 2006, 115:192-197.
130. Mohapatra J.K., Sanyal A., Hemadri D., Tosh C., Kumar R.M., Bandyopadhyay S.K. Evaluation of in vitro inhibitory potential of small interfering RNAs directed against various regions of foot-and-mouth disease virus genome. Biochem. Biophys. Res. Commun. 2005, 329:1133-1138.
131. Anderson J., Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res. Ther. 2005, 2:1.
132. Griffiths G., Rottier P. Cell biology of viruses that assemble along the biosynthetic pathway. Cell. Biol. 1992, 3:367-381.
133. Glotzer S.C. Materials science. Some Assembly Required. Science 2004, 306:419-420.
134. Gates B.D., Xu Q., Stewart M., Ryan D., Willson C.G., Whitesides G.M. New approaches to nanofabrication: molding, printing, and other techniques. Chem. Rev. 2005, 105:1171-1196.
135. Shu D., Huang L., Hoeprich S., Guo P. Construction of phi29 DNA-packaging RNA (pRNA) monomers, dimers and trimers with variable sizes and shapes as potential parts for nano-devices. J. Nanosci. Nanotechnol. 2003, 3:295-302.
136. C. Zhang, M. Trottier and P. Guo, Circularly permuted viral pRNA active and specific in the packaging of bacteriophage phi 29 DNA. Virology. 207(1995):442-451.
137. Prats A.C., Roy C., Wang P.A., Erard M., Housset V., Gabus C., Paoletti C., Darlix J.L. Cis elements and trans-acting factors involved in dimer formation of murine leukemia virus RNA. J. Virol. 1990, 64:774-783.
138. Wagner C., Ehresmann C., Ehresmann B., Brunel C. Mechanism of dimerization of bicoid mRNA: initiation and stabilization. J. Biol. Chem. 2004, 279:4560-4569.
139. Wei C., Wei W., Morris M., Kondo E., Gorbounov M., Tomalia D.A. Nanomedicine and drug delivery. Med. Clin. North Am. 2007, 91:863-870.
140. Tomalia D.A., Reyna L.A., Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 2007, 35:61-67.
141. Svenson S., Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. 2005, 57:2106-2129.
142. Kam N.W., Liu Z., Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J. Am. Chem. Soc. 2005, 127:12492-12493.
143. Herrero M.A., T.F., Al-Jamal K.T., Kostarelos K., Bianco A., Da Ros T., Bano F., Casalis L., Scoles G., P.M. Synthesis and characterization of a carbon nanotube-dendron series for efficient siRNA delivery. J. Am. Chem. Soc. 2009, 131:9843-9848.
144. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., Sood A.K. Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery. Cancer Res. 2005, 65:6910-6918.
145. Halder J., Kamat A.A., Landen C.N., Han L.Y., Lutgendorf S.K., Lin Y.G., Merritt W.M., Jennings N.B., Chavez-Reyes A., Coleman R.L., Gershenson D.M., Schmandt R., Cole S.W., Lopez-Berestein G., Sood A.K. Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin. Cancer Res. 2006, 12:4916-4924.
146. Zhang C., Tang N., Liu X., Liang W., Xu W., Torchilin V.P. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control. Release 2006, 112:229-239.
147. Burkatovskaya M., Tegos G.P., Swietlik E., Demidova T.N., Castano P., Hamblin M.R. Use of chitosan bandage to prevent fatal infections developing from highly contaminated wounds in mice. Biomaterials 2006, 27:4157-4164.
148. Hung C.F., Hwang T.L., Chang C.C., Fang J.Y. Physicochemical characterization and gene transfection efficiency of lipid, emulsions with various co-emulsifiers. Int. J. Pharm. 2005, 289:197-208.
149. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C.S., Jeffs L.B., Judge A., Maclachlan I., Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23:1002-1007.
150. Zimmermann T.S., Lee A.C.H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Rohl I., Seiffert S., Shanmugam S., Sood V., Soutschek J.R., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.-P., MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
151. Karanth H., Murthy R.S. pH-sensitive liposomes-principle and application in cancer therapy. J. Pharm. Pharmacol. 2007, 59:469-483.
152. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35:5616-5623.
153. Oishi M., Nagasaki Y., Itaka K., Nishiyama N., Kataoka K. Lactosylated Poly(ethylene glycol)-siRNA Conjugate through Acid-Labile beta-Thiopropionate Linkage to Construct pH-Sensitive Polyion Complex Micelles Achieving Enhanced Gene Silencing in Hepatoma Cells. J. Am. Chem. Soc. 2005, 127:1624-1625.
154. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2004, 12:461-466.
155. Thomas M., Lu J.J., Ge Q., Zhang C.C., Chen J.Z., Klibanov A.M. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5679-5684.
156. Xie F.Y., Woodle M.C., Lu P.Y. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today 2006, 11:67-73.
157. Schiffelers R.M., Mixson A.J., Ansari A.M., Fens M.H.A.M., Tang Q., Zhou Q., Xu J., Molema G., Lu P.Y., Scaria P.V. Transporting silence: Design of carriers for siRNA to angiogenic endothelium. J. Control. Release 2005, 109:5-14.
158. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma. Cancer Res. 2005, 65:8984-8992.
159. Howard K. Unlocking the money-making potential of RNAi. Nat. Biotechnol. 2003, 21:1441-1446.
160. Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.O., Hovgaard M.B., Schmitz A., Nyengaard J.r., Besenbacher F., Kjems J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 2006, 14:476-484.
161. Rozema D.B., Lewis D.L., Wakefield D.H., Wong S.C., Klein J.J., Roesch P.L., Bertin S.L., Reppen T.W., Chu Q., Blokhin A.V., Hagstrom J.E., Wolff J.A. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12982-12987.
162. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., Feng Y., Palliser D., Weiner D.B., Shankar P., Marasco W.A., Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23:709-717.
163. Peer D., Zhu P., Carman C.V., Lieberman J., Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4095-4100.
164. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
165. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., Kato T., Terada M., Ochiya T. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004, 32:e109.
166. Takeshita F., Minakuchi Y., Nagahara S., Honma K., Sasaki H., Hirai K., Teratani T., Namatame N., Yamamoto Y., Hanai K., Kato T., Sano A., Ochiya T. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12177-12182.
167. Kinouchi N., Ohsawa Y., Ishimaru N., Ohuchi H., Sunada Y., Hayashi Y., Tanimoto Y., Moriyama K., Noji S. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther. 2008, 15:1126-1130.
168. Moore A., Medarova Z., Potthast A., Dai G. In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe. Cancer Res. 2004, 64:1821-1827.
169. Medarova Z., Pham W., Farrar C., Petkova V., Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 2007, 13:372-377.
170. Stephanie Huth J.L.S. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J. Gene Med. 2004, 6:923-936.
171. Plank C., Anton M., Rudolph C., Rosenecker J., Krotz F. Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin. Biol. Ther. 2003, 3:745-758.
172. Schillinger U., Brill T., Rudolph C., Huth S., Gersting S., Krotz F., Hirschberger J., Bergemann C., Plank C. Advances in magnetofection-magnetically guided nucleic acid delivery. J. Magn. Magn. Mater. 2005, 293:501-508.
173. Pirollo K.F., Chang E.H. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res. 2008, 68:1247-1250.
174. Guo P. Bacterial Virus phi29 DNA-Packaging Motor and Its Potential Applications in Gene Therapy and Nanotechnology. Methods Mol. Biol. 2005, 300:285-324.
175. Kim E.M., Jeong H.J., Park I.K., Cho C.S., Moon H.B., Yu D.Y., Bom H.S., Sohn M.H., Oh I.J. Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly(ethylene glycol): In vitro and in vivo studies. J. Control. Release 2005, 108:557-567.
176. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 1996, 37:1003-1008.
177. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 1994, 269:3198-3204.
178. McGookey D.J., Fagerberg K., Anderson R.G. Filipin-cholesterol complexes form in uncoated vesicle membrane derived from coated vesicles during receptor-mediated endocytosis of low density lipoprotein. J. Cell. Biol. 1983, 96:1273-1278.
179. Suckling K.E., Ochoa B. Receptor-mediated endocytosis in steroid hormone-producing tissue. Biochem. Soc. Trans. 1987, 15:192-194.
180. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32:e149.
181. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-Containing, Cyclodextrin Polymer-Based Particles for Tumor-Targeted Gene Delivery. Bioconjug. Chem. 2003, 14:1122-1132.
182. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., Kornbrust D.J., Davis M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5715-5721.
183. Tan W.B., Jiang S., Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007, 28:1565-1571.
184. Viel T., Boisgard R., Kuhnast B., Jego B., Siquier-Pernet K., Hinnen F., Dolle F., Tavitian B. Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering (siRNAs). Oligonucleotides 2008, 18:201-212.
185. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., Feng Y., Palliser D., Weiner D.B., Shankar P., Marasco W.A., Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23:709-717.
186. Chu T.C., Twu K.Y., Ellington A.D., Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006, 34:e73.
187. Chan W.K., Belfort G., Belfort M. Stability of group I intron RNA in Escherichia coli and its potential application in a novel expression vector. Gene 1988, 73:295-304.
188. Harland R., Misher L. Stability of RNA in developing Xenopus embryos and identification of a destabilizing sequence in TFIIIA messenger RNA. Development 1988, 102:837-852.
189. Guo P. Structure and Function of phi29 Hexameric RNA that Drive Viral DNA Packaging Motor: Review. Prog. Nucleic Acid Res. Mol. Biol. 2002, 72:415-472.
190. Chiu J.J., Lee P.L., Chang S.F., Chen L.J., Lee C.I., Lin K.M., Usami S., Chien S. Shear stress regulates gene expression in vascular endothelial cells in response to tumor necrosis factor-alpha: a study of the transcription profile with complementary DNA microarray. J. Biomed. Sci. 2005, 12:481-502.
191. Guo Y., Blocker F., Xiao F., Guo P. Construction and 3-D computer modeling of connector arrays with tetragonal to decagonal transition induced by pRNA of phi29 DNA-packaging motor. J. Nanosci. Nanotechnol. 2005, 5:856-863.
192. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8:173-184.
193. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marion P., Salazar F., Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441:537-541.
194. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J.C., Yamasaki S., Itaya M., Pan Y.Z., Appukuttan B., Gibbs D., Yang Z.L., Kariko K., Ambati B.K., Wilgus T.A., DiPietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452. 591-5U1.
195. Robbins M., Judge A., Liang L., McClintock K., Yaworski E., Maclachlan I. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 2007, 15:1663-1669.
196. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., Linsley P.S. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205.
197. Oh Y.K., Park T.G. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 2009, 61:850-862.
198. Robbins M., Judge A., Maclachlan I. siRNA and Innate Immunity. Oligonucleotides 2009, 19:89-101.
199. Watts J.K., Deleavey G.F., Damha M.J. Chemically modified siRNA: tools and applications. Drug Discov. Today 2008, 13:842-855.